BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update

BioAge Labs, Inc. (NASDAQ:BIOA) saw a large growth in short interest in February. As of February 13th, there was short interest totaling 1,341,664 shares, a growth of 47.6% from the January 29th total of 909,129 shares. Based on an average daily trading volume, of 644,382 shares, the days-to-cover ratio is currently 2.1 days. Approximately 4.7% of the shares of the company are short sold. Approximately 4.7% of the shares of the company are short sold. Based on an average daily trading volume, of 644,382 shares, the days-to-cover ratio is currently 2.1 days.

BioAge Labs Trading Down 2.5%

Shares of BIOA stock opened at $21.71 on Tuesday. BioAge Labs has a twelve month low of $2.88 and a twelve month high of $24.00. The stock has a 50 day moving average of $18.46 and a 200 day moving average of $11.12. The stock has a market cap of $778.30 million, a P/E ratio of -14.28 and a beta of 1.21.

Analyst Ratings Changes

BIOA has been the topic of several recent research reports. Morgan Stanley set a $23.00 price objective on shares of BioAge Labs in a research note on Wednesday, February 4th. Piper Sandler began coverage on BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating for the company. Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, January 27th. Finally, Oppenheimer assumed coverage on shares of BioAge Labs in a report on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 target price for the company. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.67.

Insiders Place Their Bets

In other BioAge Labs news, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the sale, the chief financial officer directly owned 22,408 shares in the company, valued at approximately $441,437.60. The trade was a 54.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kristen Fortney sold 233,107 shares of BioAge Labs stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total value of $4,223,898.84. Following the completion of the sale, the chief executive officer directly owned 976,949 shares of the company’s stock, valued at $17,702,315.88. The trade was a 19.26% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 354,437 shares of company stock valued at $5,813,228. 20.82% of the stock is owned by insiders.

Hedge Funds Weigh In On BioAge Labs

A number of hedge funds have recently bought and sold shares of the business. CWM LLC increased its holdings in BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after acquiring an additional 1,053 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of BioAge Labs during the third quarter worth about $27,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of BioAge Labs during the 4th quarter worth about $77,000. Police & Firemen s Retirement System of New Jersey purchased a new position in BioAge Labs in the 2nd quarter valued at about $27,000. Finally, Nisa Investment Advisors LLC boosted its holdings in BioAge Labs by 4,219.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock worth $135,000 after buying an additional 10,000 shares during the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.